a b s t r a c t H 1 receptor histaminergic antagonist, chlorpheniramine (CPA) participates in cognitive performance in various animal models. However, little is known regarding the effects of CPA microinjection into the amygdala on emotional behavior. The purpose of this study was to investigate whether CPA microinjection into the amygdala has the same effect on two models, one anxiety-and the other fear-mediated, in various memory stages using the elevated plus maze (EPM) and the inhibitory avoidance task (IAT) tests. Two experiments were performed with seventy-two adult male Swiss mice. Behavioral testing was performed on two consecutive days, and in both experiments, before each trial, the animals received bilateral microinjections of saline (SAL) or CPA (0.16 nmol). The animals were re-exposed to the EPM or IAT 24 h after the first trial. Four experimental groups were tested: SAL-SAL, SAL-CPA, CPA-SAL and CPA-CPA. In experiment 1, a decreased open arm exploration (% open arm entries, %OAE and% open arms time, %OAT) for SAL-SAL and SAL-CPA was showed, while these measures did not decrease for the CPA-SAL and CPA-CPA groups in Trial 2. In experiment 2, an increase of retention latency in relation to training 2 for the groups SAL-SAL and CPA-SAL and a significant decrease in latency for the group SAL-CPA was revealed. These results indicate that chlorpheniramine microinjection into the amygdala impairs emotional memory acquisition and/or consolidation in the EPM and retrieval of IAT.
Introduction
Memory is considered a dynamic process that has several different phases or stages, such as acquisition, short-term memory, long term memory formation, consolidation, retrieval, maintenance, extinction and reconsolidation (Makkar et al., 2010; Abel and Lattal, 2001) . It has been demonstrated that the histaminergic system is involved on emotional memory in a state-dependent manner Zarrindast et al., 2006) . Furthermore, it has been suggested that this system may exert tonic modulatory control over emotional behavior (Santos et al., 2001 ).
Histamine (HA) acts through 4 distinct subtypes of G-proteincoupled receptors, H 1 -H 4, and data have shown that the amygdala receives afferences from the tuberomammillary nucleus of the posterior hypothalamus, the major source of brain HA (Haas and Panula, 2003) . Additionally, a high density of postsynaptically located histamine H 1 receptors has been found in the amygdala (Ryu et al., 1995) . Multiple studies document the modulation of emotional memory by H 1 histamine receptor present in the amygdala (Benetti et al., 2015; Alvares and Ruarte, 2004) . H 1 pyridylethylamine administered into the basolateral amygdala showed no effect on memory consolidation in one-trial inhibitory avoidance learning in rats submitted to early postnatal maternal deprivation (Benetti et al., 2015) . In a previous study, we tested CPA microinjections at doses of 0.016 nmol, 0.052 nmol and 0.16 nmol in the amygdala, and only the 0.16 nmol dose induced a deficit in emotional memory in mice retested in the EPM . The amygdala is a structure directly related to emotional processes and recent evidence has shown that this structure can also affect motor control (Cole et al., 2014) . Furthermore, this limbic structure has been known to play an important regulatory role in the fear/anxiety systems according to Panksep (2011) . The physical and psychological manifestations of anxiety and fear appear to share commonalities, but they are in fact two independent entities that deserve operational definitions and depend on the physical distance from a threat (Dias et al., 2013; Blanchard et al., 1993) . Anxiety is characterized as a stage that arises from general and non-specific and distal stimuli associated with an extended state of apprehension, while fear is stimulated by a specific, real and proximal threat (Davis et al., 2010) . For instance, the amygdaloid complex underlies anxiety-like and fear-like states gathering afferent inputs and distributing these to their respective efferent pathways (Dias et al., 2013; McNaughton and Corr, 2004) .
Studies have often evaluated anxiety using the EPM, a classical model to detect anxiety-like behavior (Holmes and Rodgers, 1998) . A prior maze trial provides a baseline for the acquisition and retention of memories because experience-dependent behavioral changes can be observed (Galvis-Alonso et al., 2010) . We have shown the histaminergic system participation via H 1 receptors on emotional memory modulation, using a Trial1/Trial 2 (T1/T2) protocol in an EPM test Serafim et al., 2012 Serafim et al., , 2013 . In addition to using EPM, recently, our group reported that histamine can have different effects on memory according to the emotional component of either anxiety or fear. An impairment of the emotional memory consolidation via H 1 receptor was observed when HA was microinjected into the cerebellar vermis of mice reexposed to the EPM . On the other hand, microinjections of HA in the same dose enhances memory consolidation of inhibitory avoidance learning in mice (Gianlorenco et al., 2013) , which suggests a different role for the same dose of histamine in a memory model that uses punishment. A study conducted by Daher and Mattioli (2015) showed that the amygdaloid histaminergic system could modulate anxiety-related behaviors in the EPM and impair the retrieval process in fear conditioning with a strong aversive stimulus.
Considering that previous studies conducted in our group showed a deficit in emotional memory induced by CPA (0.16 nmol) injected into the amygdaloid complex using the EPM retest model and due to the importance of amygdala participation in circuits of both anxiety and fear on memory modulation (Dias et al., 2013; McNaughton and Corr, 2004) , the aim of the present study was to investigate whether CPA microinjection into the amygdala has the same effect on two models, one anxiety-and the other fear-mediated, during various memory stages.
Methods

Animals
The experimental subjects were 72 adult male Swiss mice (Federal University of São Carlos, SP, Brazil) weighing 25-35 g at testing. The mice were housed in groups of 4 per cage (28 × 18 × 11 cm) and maintained under a 12-h light cycle (lights on at 7 a.m.) in a controlled environment at a temperature of 23 ± 1 • C and relative humidity of 50 ± 5%. Food and drinking water were provided ad libitum, except during the brief testing periods. All mice were experimentally naïve at the beginning of the study. The experimental sessions were conducted during the light period of the cycle (9 a.m-4 p.m).
Behavioral tests
2.2.1. Experiment 1: effects of intra-amygdala CPA microinjection on the emotional memory of mice in the elevated plus-maze 2.2.1.1. Elevated plus maze. EPM testing was performed similarly to methods previously developed and validated for rats (Pellow et al., 1985) and mice (Lister, 1987) . The test is widely employed to score anxiety levels in rodents (Carobrez and Bertoglio, 2005; Galvis-Alonso et al., 2010) . The apparatus was made of gray acrylic, consisted of four arms, two open arms (30 × 5.0 × 0.25 cm) and two enclosed with opaque walls (30 × 5.0 × 15.25 cm), extending from a common central platform (5 × 5 cm) and was elevated to a height of 38.5 cm from the floor. All of the tests were performed under moderate illumination (50 lx), as measured on the central platform of the EPM.
The tests were performed on two consecutive days. On the first day, the animals were exposed to the EPM (T1), and this was followed by a second trial 24 h later. The experiment began by transferring the mice to the test room, where they were allowed to rest for 1 h and then placed individually in the centre of the plusmaze facing an open arm, and allowed 5 min of free exploration. After 24 h, the animals were subjected to the same experimental procedure (T2). The maze was cleaned with ethanol (5%, v/v) to avoid possible bias due to odors and/or residues left by mice tested earlier.
All sessions were video-recorded using a digital camera positioned above the maze and linked to a computer in an adjacent room. The images were analyzed by a trained observer using the XPLOT-RAT ethological analysis software developed at the Laboratory of Exploratory Behavior, USP/Ribeirao Preto (Garcia et al., 2005) . Behavioral parameters were defined according to previous studies (Rodgers and Johnson, 1995; Lister, 1987) and included the following: frequencies of open-and enclosed-arm entries (OAE and EAE) (arm entry = all four paws within an arm), total arm entries (TE), total time spent in open arms (OAT), total time spent in enclosed arms (EAT), and total time spent in the central area (CT). These data were used to calculate the percentages of OAE [%OAE; (OAE/TE) × 100] and OAT [%OAT; (OAT/300) × 100]. An increase in open-arm avoidance with repeated maze exposure has been observed in several studies and has been used as a measure of learning and memory evaluated by T1/T2 (test/retest) protocols (Canto-de-Souza et al., 2015; Bertoglio et al., 2006) .
Experiment 2:
effects of intra-amygdala CPA injections on the emotional memory of the mice in the inhibitory avoidance task 2.2.2.1. Inhibitory avoidance task. In the present study, IAT was realized in a two-trial learning, step-through situation (Fine et al., 1985; Page et al., 1991 ). An inhibitory avoidance apparatus consisted of an acrylic box (48 × 27 × 30 cm) with two compartments of the same size, one bright (crystal colored, under illumination 400 lx, 24 × 13.5 × 15 cm) and one dark (with black acrylic, 24 × 13.5 × 15 cm), separated by a guillotine type door (7 × 7 cm) in the middle of a divider wall. The floor was made of stainless-steel rods (2.5 mm in diameter) spaced 1 cm apart that delivered electric shocks at an intensity of 0.5 mA for 3 s. The box was connected to a computer with software (Insight Equipamentos Científicos Ltda, Brazil) that triggered the functions of the apparatus, and a camera was placed above the box that recorded the sessions (Surveillance System GV-600; GeoVision, Inc.; Neihu District, Taipei, Taiwan).
Mice were left in the experimental room for 1 h before the beginning of the procedure. Animals were placed in the apparatus after 1 h of habituation in the experimental room. Each animal was gently placed into the light compartment facing the door, which was opened after 6 s, allowing its entry into the dark compartment, after which the guillotine door was lifted, and the latency of the animal crossing to the dark (shock) compartment was timed. Animals that waited more than 100 s to cross to the other side were excluded. Once the animal crossed to the next compartment with all four paws, the door was closed and the mouse was taken to its home cage. After 30 min, the animal was microinjected with CPA or vehicle into the amygdala and singly placed in a home cage for 5 min to minimize the restraining stress. In T1, the acquisition trial was followed during which the guillotine door was closed and a foot shock (0.5 mA, 3 s) was delivered immediately after the animal had entered the dark compartment. After 20 s, the mouse was removed from the apparatus and placed in the home cage. A second trial (T2) was carried out after a 2 min interval; if the mouse did not enter the dark compartment of the period after 120 s, a successful acquisition of inhibitory avoidance response was recorded. Otherwise, when the mouse entered the dark compartment a second time, the door was closed and it received the same shock as above. Twentyfour hours after the second trial, the microinjection procedure was repeated and a retention test was performed to determine memory consolidation. Each animal was placed in the light compartment for 5 s, the door was opened, and the latency was measured for entering into the dark compartment. The test session ended when the animal entered the dark compartment or remained in the light compartment for 300 s.
The apparatus was cleaned with wet cotton and 5% alcohol between the tests. The step-through latencies for entries into the dark compartment during trials 1 and 2 and the retention test were manually measured by the experimenter using a stopwatch.
Surgery and microinjection
Mice were bilaterally implanted with a 7-mm stainless steel guide cannula (25-gauge; Insight Equipamentos Científicos Ltda.) under anesthesia with intraperitoneally (IP) injected ketamine chlorhydrate (50 mg/kg, IP) and xylazine (5 mg/kg, IP) dissolved in sterile 0.9% saline solution. The surgical procedure was performed in a stereotaxic frame (Stoelting Co., Illinois, USA), and stereotaxic coordinates (Paxinos and Franklin, 2001 ) for the target site in the amygdala were measured in relation to the skull surface: antero-posterior (AP) = −0.8 mm, lateral (L) = ±2.7 mm and ventral (V) = −2.0 mm. The guide cannula was fixed to the skull using dental acrylic and jeweler's screws. During implantation, the guide cannula was aimed to terminate 1 mm above the target site. A dummy cannula (33-gauge stainless steel wire; Fishtex Industry and Commerce of Plastics Ltda.) was inserted into each guide cannula immediately after surgery to reduce the incidence of occlusion. Post-operative analgesia was provided for intramuscular injection of flunixin meglumine (2.5 mg/kg body weight).
Five days after surgical recovery, each mouse was microinjected with CPA or vehicle (saline, SAL) 5 min before the behavioral testing. The microinjection procedure consisted of gently restraining the animal, removing the dummy cannula, inserting the injection unit, infusing the solution, and keeping the injection unit in situ for an additional 60 s. The experimental solutions were injected into the amygdala using microinjection units (33-gauge stainless steel cannula; Insight Equipamentos Científicos Ltda.) that extended 1.0 mm beyond the tip of the guide cannula. Each microinjection unit was attached to a 5-l Hamilton microsyringe via polyethylene tubing (PE-10), and administration was controlled by an infusion pump (BI 2000, Insight Equipamentos Científicos Ltda.) programmed to deliver a volume of 0.1 l (volume injected) over a period of 60 s.
Experimental procedure
Experiment 1 and Experiment 2 were performed during 2 consecutive days, and the CPA or SAL was administered prior to T1 and T 2. In both experiments, the animals were randomly assigned to four groups based on drug treatment: SAL-SAL (n = 9), SAL-CPA (n = 9), CPA-SAL (n = 9) and CPA-CPA (n = 9). Injection procedure was performed in the amygdaloid complex as described by Baptista et al. (2009) 
Drugs
Chlorpheniramine maleate salt (Sigma Chemical Co., St. Louis, MO) (an H 1 receptor antagonist) was dissolved in sterile 0.9% saline solution (SAL). The CPA solution was microinjected at a dose of 0.16 nmol in a volume of 0.1 l. The doses used were based on a previous study conducted in our laboratory ).
Histology
At the end of the experiments, each animal received a 0.1 l infusion of a 1% methylene blue solution into the amygdala according to the microinjection procedure described earlier. The animals received an anesthetic overdose; their brains were removed and placed in containers with formaldehyde solution (10%). Later, the brain tissues were coronally sectioned using a cryostat microtome 300 (ANCAP, Brazil). Injection sites were microscopically (Olympus B202) verified with reference to the Atlas of Paxinos and Franklin (2001) .
Histological examination confirmed that 72 mice had accurate cannula placement in the amygdala (Fig. 1) . These individuals were used to investigate the effects of intra-amygdala CPA injections on emotional behaviors. Data from animals with injection sites outside the amygdala were excluded from analysis.
Statistical analysis
Initially, all results were submitted to Levene's test for homogeneity of variance. When appropriate, the data were square-root transformed and then analyzed using two-way repeated measures ANOVA. Differences indicated by significant F values were further verified by post hoc Duncan's multiple range tests. In all cases, a p value smaller than 0.05 was required for significance.
Ethics
All procedures were approved by the Ethics Committee on Animal Experimentation of the Federal University of São Carlos (#009/13) and were compliant with the norms of the Brazilian Neuroscience and Behavior Society (SBNeC), which are based on the US National Institutes of Health Guide for the Care and use of Laboratory Animals.
Results
3.1. Experiment 1: intra-amygdala microinjection of CPA at a dose of 0.16 nmol induces an emotional memory acquisition/consolidation deficit in the EPM Fig. 2(A) and (B) shows the treatment effects of intra-amygdala infusion of SAL or CPA (0.16 nmol) on EPM behavioral measures. Two-way ANOVA revealed no significant treatment effects for%OAE [F (3,32) = 1.39, p > 0.05] and%OAT [F (3,32) = 0.95, p > 0.05] or OAE and OAT (p > 0.05). Post hoc testing did not show significant differences between SAL-SAL and CPA-SAL or CPA-CPA groups in T1 (Table 1) for these measures, indicating that the drug did not induce changes in anxiety state. Furthermore, ANOVA followed by Duncan's test showed no significant difference between groups for EAT, CT and EAE (p > 0.05 for all) during T1, as shown in Table 1 Fig. 2A and B Both drugs were administered prior to each trial. Groups: SAL-SAL (n = 9), SAL-CPA (n = 9), CPA-SAL (n = 9) and CPA-CPA (n = 9). *p < 0.05 for T1 compared with T2 (ANOVA followed by Duncan's post hoc test).
SAL-CPA groups. The post hoc test also indicated a significant decrease in OAE and OAT (p < 0.05) for these groups. Importantly, %OAE and%OAT did not decrease for the CPA-SAL and CPA-CPA in Trial 2 ( Fig. 2A and B) . In addition, as indicated by ANOVA followed by post hoc comparisons, the T2 EAT increased [F (1,32) = 20.31, p < 0.05] for the SAL-SAL group, but EAE and TE did not differ significantly between trials for any of the experimental groups (p > 0.05). Table 1 Effects of intra-amygdala injections of SAL or CPA (0.16 nmol) prior to Trial 1 (T1) and prior to Trial 2 (T2) on behavioral measures in mice re-exposed to EPM testing. Data are reported as mean ± SEM. TE = total entries; CT = time spent in the central area; EAT = time spent in enclosed arms; OAE = open arm entries; OAT = time spent in open arms; *p < 0.05 for T1 compared to T2 (ANOVA, followed by Duncan's post hoc test).
Fig. 3. Means and Standard
Error of the Mean (±SEM) of latencies in mice of transition toward the dark compartment for intra-amygdala pre-Tria1 and pre-test saline (SAL) or CPA microinjected groups. Groups: SAL-SAL (n = 9), SAL-CPA (n = 9), CPA-SAL (n = 9) and CPA-CPA (n = 9) submitted to an inhibitory avoidance task. *p < 0.05 (difference between Trial 1 and 2; Duncan's post hoc test). #p < 0.05 (difference between training 2 and test).
Duncan's test also indicated that CT decreased for the SAL-SAL and CPA-CPA groups (Table 1) .
3.2. Experiment 2: intra-amygdala injections of CPA at a dose of 0.16 nmol induce an emotional memory retrieval deficit in the inhibitory avoidance task Fig. 2 shows the results of comparisons between latencies recorded during training on acquisition 1, training on acquisition 2 and tests in the various experimental groups that underwent an inhibitory avoidance task.
Comparing the latencies of training 1 and training 2, a twoway ANOVA indicated a significant difference between sessions of the inhibitory avoidance task [F (2,32) = 23.54, p < 0.05]. The Duncan's post hoc test showed a significant increase in latency during training 2 compared with that recorded in training 1 for all experimental groups: SAL-SAL, SAL-CPA, CPA-SAL and CPA-CPA (Fig. 3) .
A two-way ANOVA indicated differences between sessions, and the Duncan's test revealed an increase of retention latency in relation to training 2 for the groups SAL-SAL and CPA-SAL (Fig. 2) . However, there was a significant decrease in latency in the retention test compared with training 2 in the group SAL-CPA, indicating that CPA impaired the retrieval of emotional memory in mice submitted to the inhibitory avoidance task.
Discussion
The present study assessed the effects of a single previously shown efficient dose of CPA (0.16 nmol) on emotional memory investigated through two different experimental paradigms: the elevated plus maze and inhibitory avoidance task. Our results demonstrate that CPA microinjection into the amygdala induced emotional memory acquisition and consolidation deficit in the EPM. Additionally, we show that CPA impairs emotional memory retrieval in an IAT.
4.1. Intra-amygdala CPA microinjection prior to testing impairs the emotional memory acquisition and/or consolidation of mice in the elevated plus maze test
In experiment 1, we evaluated the effects of microinjections of CPA in anxiety-like states in mice submitted to the EPM, a classical model used to investigate anxiety-like behavior. Our results show that intra-amygdala infusion with CPA (0.16 nmol) did not appear to affect anxiety because there was no significant difference between the SAL-SAL and the groups that received CPA injections prior to T2 (SAL-CPA group) and prior to T1 and T2 (CPA-CPA group). Some studies have shown a histaminergic modulation of anxiety in the EPM and in other models. Intra-dorsal hippocampal injection of CPA reverses the anxiolytic-like effects of l-histidine in mice exposed to EPM (Canto-de-Souza et al., 2015) . Systemic injection and local injection of CPA into the medial portion of the prefrontal cortex (mPFC) attenuated anxiety and fearful responses in mice through the activation of the serotoninergic system (5-HT) (Miyata et al., 2011) . These discrepancies concerning the modulation exerted by H 1 receptors may be related to the differences in injection sites, age and species of animals used to evaluate anxietylike responses.
Emotional memory can be inferred by analyzing the exploratory behavioral profile of animals in the EPM, using the T1/T2 protocol. Our results show impairment in emotional memory acquisition and/or consolidation because there was no decrease in exploratory activity in the open arms (%OAE and%OAT) in Trial 2 for the group treated with CPA prior to T1, indicating that these mice did not remember aversive information about the open arms during T2. The inclusion of a retest session is consistent with the assumption that there is a learned component underlying the exploratory behavior during EPM re-exposure (Galvis-Alonso et al., 2010) . The present results demonstrate that histamine via H 1 receptors impairs emotional memory acquisition and/or consolidation in mice submitted to an EPM and replicate a study conducted by our group that suggests an inhibitory role of CPA at a dose of 0.16 nmol microinjected into the amygdala on the emotional memory in mice re-exposed to the EPM . Although the pharmacological blockade of the H 1 receptor with CPA improved spatial learning in the Morris Water Maze (Masuoka et al., 2010) , our data are in accordance with other behavioral studies conducted by our research group that have shown impairment in learning and memory induced by CPA in the EPM (Serafim et al., 2013; Canto-de-Souza et al., 2015) . Thus, our studies indicate that this drug has a distinct effect on anxiety models and spatial memory.
4.2. Intra-amygdala CPA microinjection prior to testing impairs the fear memory retrieval of mice in the inhibitory avoidance task
In addition to the EPM test, we investigated the emotional behavioral response using the inhibitory avoidance tasks, a model that uses punishment. In experiment 2, we demonstrated that CPA by itself when microinjected into the amygdala prior to the retention test impaired memory retrieval, as observed in decreased latencies for SAL-CPA mice. The amnesic effect is indicated by the comparison among the lower test latencies of this group, in relation to its respective trial latency, and the higher test latencies of control and CPA-CPA mice. These latter groups exhibit fear conditioning, which is inferred from increased retention latencies. The present result is supported by the drug's influence on sessions according to ANOVA. However, the acquisition memory is not impaired by CPA because there was no difference between the saline-and CPA-treated groups in trials 1 and 2. Thus, intraamygdala administration of CPA induces amnesic effect in the evocation of aversive information in mice submitted to the IAT. In a study conducted by Benetti and Izquierdo (2013) , the promnesic action of histamine was unaffected by the H 1 receptor antagonist microinjected in basolateral amygdala in the consolidation of aversive memory in rats trained in a one-trial step-down inhibitory avoidance task (Benetti and Izquierdo, 2013) . The different results could be explained by histamine presents a non-linear response called an "inverted U-shaped dose effect curve" (IUS-DEC), which is frequently showed when studying the actions of pharmacological treatments in experiences with emotional valence (Gianlorenco et al., 2013) . Emotional arousal has been invoked as an essential endogenous modulator of memory processes and it is based on the finding that the arousal state can interact with exogenously supplied mnemonic active agents to alter their effectiveness at any given dosage (McGaugh, 1989) .
Fear conditioning is an effective experimental paradigm that enables the various memory phases to be assessed separately (Nonankan et al., 2013) . In a recent study, the blockade of the H 1 receptor with Diphenhydramine impaired the consolidation expression of contextual fear memory but had no effect on the acquisition of contextual fear memory or on the acquisition and consolidation of extinction memory in mice (Nonankan et al., 2013) . These results suggest that the pattern of impairment produced by CPA on emotional memory phases would be related to the timing of drug injections during testing with the IAT (experiment 2) and EPM (experiment 1) because memory consists of several phases (Makkar et al., 2010; Rodrigues et al., 2004) , and these phases have been demonstrated to be different in their sensitivity to drugs.
General discussion
Taken together, these results (experiment 1 and experiment 2) contribute to explaining the effects produced by CPA on different experimental paradigms used to assess aversive memory. The two experimental models used in this study allowed the evaluation of aversive memory, but these models are related to distinct behavioral paradigms: the EPM, which is based on the innate avoidance of potentially threatening areas acquired on the first test, is related to anxiety; and the IAT, which is based on the conditioned avoidance to a real danger, is related to fear expression. The histaminergic system via H 1 receptor present in the amygdala could modulate aversive memory while simultaneously modifying neurochemical systems, such as acetylcholinergic, underlying different categories of emotion, e.g., anxiety and fear. It has been speculated that CPA possesses antimuscarinic effects (Yasuda and Yasuda, 1999) , and histamine acting on H 1 receptors may depend at least in part on influences of cholinergic transmission (see Khateb et al., 1995) . A previous study conducted in our laboratory reported that the combined microinjections of CPA (0.16 nmol) and PNU-282987, a selective agonist of the alpha 7 nicotinic cholinergic receptor, reversed the amnesic effects caused by CPA. This finding is suggestive of an interaction between the histaminergic and cholinergic systems in the modulation of emotional memory acquisition and consolidation in mice re-exposed to the EPM (FERNANDES et al., 2015, submitted) . Therefore, we suggest that only the highest dose of H 1 antagonist chlorpheniramine microinjected into the amygdala could lead to decreased acetylcholinergic activity in this structure, which impairs the emotional memory acquisition and/or consolidation in the LCE. Conversely, retrieval was affected in experiment 2; therefore, these results may be due to the interactions between the amygdala and serotonergic systems (Liang, 1999) . Intra-central amygdala pre-test injection with a selective 5-HT1A receptor antagonist inhibited the improvement of morphine-induced amnesia retrieval that was produced by pre-test co-injection of nicotine in rats submitted to the passive avoidance task (Tirgar and Rezayof, 2014) .
Nevertheless, another possible interpretation is that the amygdala participates in the circuits of anxiety and fear (McNaughton and Corr, 2004) , exerting effective modulation over the activity of other brain structures that contribute to the strengthening of memories by triggering changes in synaptic strength (Pape and Pare, 2010; Rodriguez-Duran et al., 2011) .
Previous studies conducted in our group research showed that cerebellar histaminergic system participation in the consolidation of emotional memory is dependent on an anxiety or fear component (Gianlorenco et al., 2013) ; furthermore, the amygdalar histaminergic system induces impairment in the aversive memory in IAT but not in the EPM, suggesting that HA modulates the systems involved in anxiety and fear learning differently (Daher and Mattioli, 2015) . Furthermore, the operational need to define anxiety versus fear arises from the conceptions that these two categories of emotion are mediated by shared as well as independent subsystems in the brain (Davis et al., 2010) . Although, the symptoms of fear and anxiety are very similar, they differ in terms of certain key dimensions and can be treated with independent therapeutic strategies (Davis et al., 2010) . We suggest that the Histaminergic system via H 1 receptor present in the amygdala induces impairment in emotional memory expression related to anxiety and fear.
Therefore, together with the findings of previous studies, our results are concurrent with the hypothesis that the histaminergic system could provide a crucial mechanism for fine-tuning the amygdala for an adequate behavioral response.
Conclusions
These results indicate that chlorpheniramine microinjection into the amygdala induces an inhibitory effect at certain stages of emotional memory: acquisition and/or consolidation in the EPM and retrieval in the IAT.
